Case Report - (2022) Volume 16, Issue 6
Received: 02-Aug-2022, Manuscript No. JCST-22-001; Editor assigned: 08-Aug-2022, Pre QC No. JCST-22-001; Reviewed: 22-Aug-2022, QC No. JCST-22-001; Revised: 26-Aug-2022, Manuscript No. JCST-22-001; , DOI: 10.37421/2376-1318.2024.13.345
Cholestatic jaundice as the initial symptom in patients with metastatic prostate cancer is extremely rare. Few cases only of paraneoplasic cholestatic jaundice associated with prostate cancer have been reported in the literature. We present a case of 57 years old patient who presented cholestatic jaundice revealing an underlying metastatic prostate cancer after detailed examinations including Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positon Emission Tomography (PET), and Endoscopic Retrograde Cholangiopancreatography (ERCP). Cholestatic jaundice may be brought on by malignancies via identified pathways (e.g., bile duct obstruction or widespread hepatic infiltration). Through an unknown pathogenetic mechanism, paraneoplastic syndromes connected to malignancy, particularly renal cell carcinoma (Stauffer's syndrome) and malignant lymphoproliferative disorders, can cause a reversible form of cholestasis. There have been two cases documented in the medical literature of prostate cancer that originally manifested as cholestatic jaundice without any clear reason (i.e., blockage or invasion). We describe a patient who had pruritus and cholestatic jaundice when they first arrived. The diagnosis of prostate cancer was made throughout the diagnostic process. Conjugated bilirubin and alkaline phosphatase levels significantly rose, but transaminase and glutamyltranspeptidase levels only slightly increased. No signs of extrahepatic biliary blockage or hepatic metastases were found, according to the findings of the necessary studies carried out while the patient was hospitalised.
troduction Cholestasis in patients suffering from malignancies can typically result from a bile duct obstruction either by the primary tumor itself, metastasis to the liver, or enlarged lymph nodes [1,2]. More rarely, in patients with advanced prostate cancer known as a silent cancer. However, prostate cancer presenting as cholestatic jaundice is extremely rare, and only very few cases of paraneoplastic cholestatic jaundice associated with prostate cancer have been reported in the literature [3-5]. Here, we describe a case of a patient with metastatic prostate cancer who presented with cholestatic jaundice and was treated with both surgical castration and chemotherapy.
A 57 year old man was referred to our hospital because of jaundice, anorexia and weight loss which had persisted for 4 months with abdominal pain, dark urine, light-colored stools and pruritus. The liver and spleen were not palpable. Digital rectal examination revealed a stony hard prostate.
U/L), gamma-glutamyltransferase of 1420 U/L (Normal range: 9-64 U/ L), and total bilirubin of 16.2 mg/Dl (Normal range: 0.3-1 mg/dL), with direct bilirubin of 10.7 mg/dL (Normal range: ≤ 0.18). Prost
Cancer Science & Therapy received 5332 citations as per Google Scholar report
